BioCryst reports Q1 EPS ($2.98), consensus 11c

Reports Q1 revenue $156.41M, consensus $151.12M. BioCryst (BCRX) recorded a GAAP operating loss of $701.6M for the first quarter, primarily reflecting the special, non-cash charge related to acquired in-process research and development. “We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”